OncoZenge AB
ONCOZ.XSTO
OncoZenge AB is a pharmaceutical company focusing on the development of specialized treatments targeting oncology. The primary purpose of OncoZenge AB is to innovate and deliver therapeutic solutions that address unmet medical needs in cancer care, particularly in the domain of mucositis and other cancer-related conditions. By concentrating its research efforts in these niche segments, OncoZenge aims to relieve patients of the side effects associated with cancer treatments, enhancing quality of life and overall treatment outcomes. OncoZenge AB operates within the broader healthcare industry, an essential sector that has a significant impact on enhancing global public health outcomes. It utilizes advanced biopharmaceutical methodologies, which integrate cutting-edge technology and research capabilities to push the boundaries of conventional cancer treatment. In the financial market, OncoZenge AB holds a specialized position owing to its commitment to addressing specific niche areas within oncology. Therefore, it plays a crucial role in the pharmaceutical landscape, contributing not only to innovative healthcare solutions but also to the comprehensive development of the oncology market.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 6M
Net Income (TTM)
-kr 26M
▼ -83.5% YoY
Op. Margin
-439.80%
ROIC
-96.21%
▼ -48.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 24M
▼ -49.0% YoY
Op. Cash Flow (TTM)
-kr 24M
▼ -49.0% YoY
Net Debt
kr 4M
Cash & Equiv.
kr 4M
Continue Research
Peers
Biotechnology · Pick stocks to compare with ONCOZ.XSTO
OncoZenge AB (ONCOZ.XSTO) in four numbers
Questions about OncoZenge AB
Is OncoZenge AB (ONCOZ.XSTO) overvalued?
At €0.23, OncoZenge AB's price is 210% above the €0.07 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is OncoZenge AB's fair value?
Intrinsiqq's calculator puts OncoZenge AB's fair value at €0.07 a share. It grows revenue per share 5% a year for 5 years, applies an exit P/S of 2.5, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of €0.06. Every input can be changed on the Intrinsic Value tab.
Is OncoZenge AB a high-quality business?
OncoZenge AB scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is share count change at 19.9%. The Quality tab shows every check against its target.
Does OncoZenge AB (ONCOZ.XSTO) pay a dividend?
No. OncoZenge AB (ONCOZ.XSTO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ONCOZ.XSTO
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.